Phase 1 Colorectal Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have been diagnosed with bowel cancer (starting in the colon or rectum) that has spread to other parts of the body (Stage IV), confirmed by a tissue test
- People whose cancer has been tested and found to be a specific type called MSS and/or "proficient mismatch repair" (confirm with trial site if unsure what this means)
- People whose cancer got worse during treatment, or within 3 months after finishing their last cancer treatment for the spread of the disease
- People whose cancer can be measured on scans, using a standard set of measurement rules called RECIST v1.1
- People who are expected by their doctor to live at least 12 weeks or more
- People who are reasonably active and able to care for themselves, as measured by a standard scale called ECOG Performance Status 0 or 1 (confirm with trial site)
- People whose heart, blood, and kidney function meet the required levels based on test results
Who may not be able to join:
- People who are pregnant, breastfeeding, or planning to become pregnant
- People who have cancer that has spread to the brain or spinal cord and is currently active
- People who have had a different type of cancer in the past (other than the one being studied in this trial)
- People who still have unresolved side effects from previous cancer treatments such as radiation, chemotherapy, targeted therapy, or surgery
- People who have had major surgery or a serious physical injury within 4 weeks before the start of the trial treatment, or who are expected to need major surgery during the trial (routine tissue biopsies are not included in this)
- People who have a confirmed positive test result for HIV
- People who test positive for Hepatitis B at the screening stage
- People who test positive for Hepatitis C at the screening stage
- People who have received any cancer treatment or experimental treatment within 4 weeks (or a shorter period depending on how the treatment works in the body) before the trial begins
- People who have previously been treated with a therapy that targets a protein called CEA, or who have received systemic radiation therapy in the past
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Clinical Trials, Hoffmann-La Roche
Phone: 888-662-6728 (U.S. and Canada)
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Part 1: Serum Concentration of SPLIT Abs; Part 1: Time Course of Blood, Plasma, and Urine Radioactivity for 203Pb-DOTAM; Part 1 to 2: Absorbed Radiation Dose of 212Pb-DOTAM extrapolated from 203Pb-DOTAM; Part 1 to 3: Percentage of Participants With Adverse Events (AE)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 6 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.